586 BODY WEIGHT AND MICROVASCULAR DYSFUNCTION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AT LOW CARDIOVASCULAR RISK REFERRED TO POSITRON EMISSION TOMOGRAPHY

Abstract Introduction Whether obesity, a modifiable risk factor in patients with hypertrophic cardiomyopathy (HCM), can influence coronary microvascular dysfunction (CMD) is unknown. Objective To assess the relationship between body weight and CMD measured myocardial blood flow (MBF) at positron emission tomography (PET) HCM. Methods All consecutive HCM referred to PET scan from 2010 2020 were reviewed. Only cardiac magnetic resonance (CMR) analysis, <60 years old diagnosis, no history of diabetes, dyslipidemia, hypertension included. Patients classified into three groups according baseline BMI: BMI<25 kg/m2, BMI 25-30 BMI>30 kg/m2. Results Of 1512 HCM, 134 (8.9%) had been 79 (5.2%) met inclusion criteria (29% women, median age was 44 [28-53] years). Overall, 52% 37% 11% >30 At PET, average MBF 2.08 [1.52-2.40] ml/min/g similar among (p=0.288) irrespective fibrosis CMR. Prevalence severe (MBF <1.53 ml/min/g: (9 [22%] vs 8 [28%] 2 [22%], study groups, p=0.833). Age atrial fibrillation associated MBF. Conclusions Obesity not worsening patients. These findings support hypothesis that worse symptomatic profile obese due increased prevalence obstruction rather than accentuation structural phenotype. Thus, handicap obesity may be reversible following appropriate weight-reduction strategies